The 55 references in paper E. Kornilova V., A. Ermolaeva D., M. Rusanova G., D. Andreev A., M. Davydovskaya V., T. Ermolaeva N., A. Pokatilo g, K. Polyakova I., V. Dubovtseva A., K. Kokushkin А., A. Devyatkin V., Е. Корнилова Б, А. Ермолаева Д., М. Русанова Г., Д. Андреев А., М. Давыдовская В., Т. Ермолаева Н., А. Покатило Г., К. Полякова И., В. Дубовцева А., А. Кокушкин А., А. Девяткин В. (2017) “Стратегии лекарственного обеспечения пациентов с хроническим вирусным гепатитом С // The strategies of drug supply for patients with chronic hepatitis C” / spz:neicon:pharmacoeconomics:y:2017:i:3:p:34-46

1
Clinical recommendations of the International Association of Infectious Diseases Specialists (“IASO”) – 2016. Chronic viral hepatitis C in adults [Klinicheskie rekomendatsii Mezhdunarodnoi assotsiatsii spetsialistov v oblasti infektsii («MASOI») – 2016 g. Khronicheskii virusnyi gepatit C u vzroslykh (in Russian)].
(check this in PDF content)
2
Simmons B. et al. Long-Term Treatment Outcomes of Patients Infected with Hepatitis C Virus: A Systematic Review and Meta-analysis of the Survival Benefit of Achieving a Sustained Virological Response. Clin Infect Dis. 2015; 61 (5): 730-40.
(check this in PDF content)
3
Yaroshenko E. B., Moisyuk Ya. G. Transplantologiya (in Russian). 2010; 1: 112-114.
(check this in PDF content)
4
Got’e S. V., Moisyuk Ya.G., Poptsov V. N., Kornilov M. N., Yaroshenko E. B., Pogrebnichenko I. V., Moisyuk L. Ya., Sushkov A. I., Malinovskaya Yu.O., Tsoi D. L. Vestnik transplantologii i iskusstvennykh organov (in Russian). 2014; 16 (3): 45-53.
(check this in PDF content)
5
Kornilova E., Kornilov M., Moysyuk Ya., Gautier S. Evaluation Of Results HCV Treatment After Liver Transplantation. Transplantation. May 2016; 100 (5S): 181.
(check this in PDF content)
6
Kornilova E., Tsirulnikova O., Kornilov M., Gautier S. HCV treatment after liver transplantation 2006-2016: result assessment. Transplantation. July 2016; 100 (7S): 573.
(check this in PDF content)
7
EUROPEAN LIVER TRANSPLANT REGISTRY. URL: http://www. eltr.org/Specific-results-by-disease.html. Accessed: 20.07.17
(check this in PDF content)
8
EASL recommendations on treatment of hepatitis C 2016. Journal of Hepatology. AASLD and IDSA Recommendations for Testing, Managing, and Treating Hepatitis C. 2016.
(check this in PDF content)
9
Mauss S., Buggish P., Boker K. H. W., Schott E., Klinker H., Gunther R. Treatment outcomes for hepatitis C genotype 1 infection with direct acting antivirals: data from the German Hepatitis C Registry. Journal of Hepatology. 2016; 64: 820.
(check this in PDF content)
10
Sulkowski M. S., Vargas H. E., Di Bisceglie A. M., Kuo A., Reddy K. R., Lim J. K. et al. Effectiveness of simeprevir plus sofosbuvir, with or without ribavirin, in real-world patients with HCV genotype 1 infection. Gastroenterology. 2016; 150: 419-429.
(check this in PDF content)
11
EASL Clinical Practice Guidelines: Management of hepatitis C virus infection. J Hepatol. 2011; 55: 245-264. EASL Clinical Practice Guidelines: Management of hepatitis C virus infection. Journal Of Hepatology. 2014; 60: 392-420.
(check this in PDF content)
12
Report on the incidence of viral hepatitis B and C in the Russian Federation FBUN CRI Epidemiology Rospotrebnadzor 2016 [Otchet po zabolevaemosti virusnymi gepatitami B i C v Rossiiskoi Federatsii FBUN TsNII Epidemiologii Rospotrebnadzora 2016 g. (in Russian)]
(check this in PDF content)
13
Petruzziello A. et.al. Global epidemiology of hepatitis C virus infection: an up-date of the distribution and circulation of hepatitis C virus genotypes. World Journal of Gastroenterology. 2016 September
(check this in PDF content)
14
22 (34): 7824-7840. 14. Nikitin I., Popovich L. D., Potapchik E. G. Epidemiologiya i infektsionnye bolezni. Aktual’nye voprosy (in Russian). 2015; 6: 9-13.
(check this in PDF content)
15
Shestakova I., Popovich L. D., Potapchik E. G., Blokhina N. Epidemiologiya i infektsionnye bolezni. Aktual’nye voprosy (in Russian). 2016; 2: 15-24.
(check this in PDF content)
16
Afdhal N. et al. Ledipasvir and sofosbuvir for previously treated HCV genotype 1 infection. N Engl J Med. 2014; 370 (16): 1483-93.
(check this in PDF content)
17
Afdhal N. et al. Ledipasvir and sofosbuvir for untreated HCV genotype 1 infection. N Engl J Med. 2014; 370 (20): 1889-98.
(check this in PDF content)
18
Jacobson I. M, McHutchison J. G., Dusheiko G. et al. Telaprevir for previously untreated chronic hepatitis C virus infection. N Engl J Med. 2011; 364: 2405-16.
(check this in PDF content)
19
Manns M et al. The Lancet. 2-8 August 2014; 384 (9941): 414426. ФАРМАКОЭКОНОМИКА. Современная фармакоэкономика и фармакоэпидемиология. 2017; Том 10, No 3 www.pharmacoeconomics.ru
(check this in PDF content)
20
Kwo P. et al. Hepatology. 2016 Aug; 64 (2): 370-80. DOI: 10.1002/hep.28467. Epub 2016 Mar 22.
(check this in PDF content)
21
Manns M. et al. All-oral daclatasvir plus asunaprevir for hepatitis C virus genotype 1b: a multinational, phase 3, multicohort study. Lancet. 2014; 384: 1597-1605.
(check this in PDF content)
22
Sulkowski M. S. et al. The New England Journal of Medicine. 2014; 370: 211-221.
(check this in PDF content)
23
Kowdley K. et al. N Engl J Med. 2014; 370: 1879-88.
(check this in PDF content)
24
Afdhal N. et al. N Engl J Med. 2014; 370: 1889-98.
(check this in PDF content)
25
Afdhal N. et al. N Engl J Med. 2014; 370: 1483-93.
(check this in PDF content)
26
Andreone P. et al. Gastroenterology. August 2014; 147 (2): 359-365.
(check this in PDF content)
27
Ferenci P. et al. N Engl J Med. 2014; 370: 1983-1992.
(check this in PDF content)
28
Zeuzem S. et al. Ann Intern Med. 2015; 163 (1): 1-13.
(check this in PDF content)
29
Feld J. et al. N Engl J Med. 2015; 373: 2599-607.
(check this in PDF content)
30
Cousien A. et al. Hepatitis c treatment as prevention of viral transmission and liver-related morbidity in persons who inject drugs. Hepatology. 2015; 63 (4): 1090-101.
(check this in PDF content)
31
International Monetary Fund. Download entire World Economic Outlook database. Washington (DC): International Monetary Fund. 2015.
(check this in PDF content)
32
Tarn Y. H., Hu S., Kamae I., Yang B. M., Li S. C., Tangcharoensathien V., Teerawattananon Y., Limwattananon S., Hameed A., Aljunid S. M., Bapna J. S. Health-care systems and pharmacoeconomic research in Asia-Pacific region. Value Health. 2008 Mar; 11 (1): 137-55.
(check this in PDF content)
33
Hoofnagle J. H., Sherker A. H. N. Therapy for hepatitis C – the costs of success. Engl J Med. 2014 Apr 17; 370 (16): 1552-3.
(check this in PDF content)
34
Lim S. G., Amarapurkar D. N., Chan H. L., Crawford D. H., Gane E. J., Han K. H., Ahn S. H., Jafri W., Jia J., Kao J. H., Lesmana L. A., Lesmana C. R., Mohamed R., Phiet P. H., Piratvisuth T., Sarin S.K, Sollarno J. D., Eguchi Y., Mahtab M. A., Lee K. H. Reimbursement policies in the Asia-Pacific for chronic hepatitis B. Hepatol Int. 2015 Jan; 9 (1): 43-51.
(check this in PDF content)
35
Gilead Sciences. Chronic hepatitis C treatment expansion: generic manufacturing for developing countries. Foster City (CA): Gilead. 2009.
(check this in PDF content)
36
Suthar A. B., Harries A. D. A public health approach to hepatitis C control in low- and middle-income countries. PLoS Med. 2015 Mar; 12 (3): e1001795.
(check this in PDF content)
37
Wei L., Lok A. S. Impact of new hepatitis C treatments in different regions of the world. Gastroenterology. 2014 May; 146 (5): 1145-50.e1-4.
(check this in PDF content)
38
AASLD-IDSA. Recommendations for testing, managing, and treating hepatitis C. URL: http://hcvguidelines.org/. Accessed:20.07.17
(check this in PDF content)
39
US GAO. An overview of approaches to negotiate drug prices used by other countries and US private payers and dederal programs, 2015.
(check this in PDF content)
40
U. S. Congressional Budget Office. Prescription drug pricing in the private sector. 2015.
(check this in PDF content)
41
Saag M. S. Editorial Commentary: Getting Smart in How We Pay for HCV Drugs: KAOS vs CONTROL. Clin. Infect. Dis. 2015; 61 (2): 169-170.
(check this in PDF content)
42
US Senate Committee on Finance. The Price of Sovaldi and its impact on the U. S. Health Care System. 2016.
(check this in PDF content)
43
Alison D. Marshall. Restrictions for reimbursement of interferonfree direct acting antiviral therapies for HCV infection in Europe. Journal of Hepatology. 2017; 66: 95-96.
(check this in PDF content)
44
Marshall A. Late breaker poster session EASL 2017. Australia. Abstract: Restrictions for reimbursement of interferon-free directacting antiviral therapies for HCV infection in Europe. (LBP-505).
(check this in PDF content)
45
IMS INSTITUTE FOR HEALTHCARE INFORMATICS. URL: https:// www.imshealth.com/files/web/IMSH%20Institute/Healthcare%20 Briefs/IIHI_Comparison_of_HepatitisC_Treatment_Costs.pdf. Data obrashcheniya:
(check this in PDF content)
46
Ciccozzi M. Phylogeny and phylodinamic of Hepatitis C in Italy. Paper presented at International Conference on Epidemiology & Evolutionary Generics. Orlando, FL. 2013 Aug 21-23.
(check this in PDF content)
47
Strategic Plan for the Treatment of Hepatitis C National Health System. General Secretary of Health and Consumers. Spain. 2015 May 21. Hepatitis C in the UK 2015 report. Public Health England. 2015 July.
(check this in PDF content)
48
Hepatitis C in the UK 2015 report. Public Health England. 2015 July.
(check this in PDF content)
49
ClinicalTrials.gov, U. S. National Library of Medicine. URL: https://clinicaltrials.gov. Accessed: 20.07.17
(check this in PDF content)
50
Nikitin I. G., Chulanov V. P. Epidemiologiya i infektsionnye bolezni. Aktual’nye voprosy (in Russian). 2016; 1: 4-11.
(check this in PDF content)
51
Report on the results of the evaluation of the availability of drugs based on the analysis of consumer prices and drug pricing in the Russian Federation (including in the context of the subjects of the Russian Federation) and in comparable markets of countries, including those in the CIS. European Union and BRICS, FAS Russia. 2013. URL: http://www.fas.gov.ru/analyticalmaterials/analytical-materials_31072. html. Accessed: 20.07.17
(check this in PDF content)
52
Mel’nikova L. S., Fedyaev D. V., Gerasimova K. V. Zlokachestven nye opukholi (in Russian). 2016; 4 (1S): 99-102.
(check this in PDF content)
53
Fedyaev D. V., Fedyaev D. V., Maksimova L. V., Omel’yanovskii V. V. Meditsinskie tekhnologii. Otsenka i vybor (in Russian). 2014; 3: 25-31.
(check this in PDF content)
54
Medsi – network of clinics. URL: https://medsi.ru/about/presscentr/news/medsi-vklyuchaetsya-v-risk-shering/. Accessed: 20.07.17
(check this in PDF content)
55
Popovich L. D. Kremlevskaya meditsina. Klinicheskii vestnik (in Russian). 2013; 2: 8-14. Сведения об авторах: Корнилова Екатерина Борисовна – к. м.н., врач-терапевт, гастроэнтеролог, ведущий научный сотрудник отдела лекарственного обеспечения и фармакоэкономического анализа ГБУ «ЦКИОМТ ДЗМ». Адрес: ул. Минская, д. 12, корп. 2, Москва, Россия, 121096. E-mail: ekaterinakornilova2017@mail.ru.
(check this in PDF content)